Schizophrenia drug gains new indication for maintenance treatment
Seroquel XR from AstraZeneca has gained a new indication: for maintenance treatment of schizophrenia in adults
AstraZeneca's Seroquel XR (quetiapine fumarate) Extended-Release Tablets have been approved for maintenance treatment of schizophrenia in adult patients. This follows an earlier approval, in May, for acute treatment of schizophrenia in adult patients. The Wilmington, Del., firm explained that schizophrenia patients often suffer relapses, so Seroquel XR will provide a new long-term treatment option for them.
Click here to see more articles from Drug Topics Daily News.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
